Gordon Brown, DO, co-chair of the CME program at the 2024 LUGPA Annual Meeting, shares key insights from the conference’s CME program, highlighting the rapid advancements in GU oncology and their implications for patient care. As Dr. Brown shares, the program showcased groundbreaking developments in bladder, kidney, and prostate cancer, including updates on high-risk non-muscle invasive bladder cancer and renal cell carcinoma provided by Dr. Tom Jayram. Dr. Scott Eggener explored cutting-edge diagnostic and therapeutic technologies in prostate cancer, while Dr. Ronney Abaza discussed innovations in robotic surgery aimed at improving outcomes in minimally invasive prostatectomies. ...
Renal Cell Carcinoma
Advertisement
Latest News
Dr. Jayram breaks down important topics in kidney cancer from LUGPA 2024, including adjuvant pembrolizumab post-nephrectomy.
Utilizing bevacizumab during breaks in pazopanib treatment can result in lesser toxicity while binding and neutralizing VEGF.
The panelists discuss promising new advancements and novel therapies for treating RCC, including LAG-3 and CAR-T therapies.
The panel discusses how designing effective trials could refine the approach to treatment strategies for RCC.
Part 3 of this roundtable examines adjuvant pembrolizumab and the role of TKIs in treatment sequencing for RCC.
The panelists examine the data on TKIs and immunotherapy for RCC from the TiNivo-2 trial.
Advertisement
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Dr. Jayram breaks down important topics in kidney cancer from LUGPA 2024, including adjuvant pembrolizumab post-nephrectomy.
Dr. Jayram provides insights into the BCG-unresponsive and BCG-naive bladder cancer space at the LUGPA 2024 Annual Meeting.
Dr. Hafron breaks down the most important updates in upper tract urothelial carcinoma from the LUGPA 2024 Annual Meeting.
Dr. Daneshmand talks about key studies and exciting developments in bladder cancer from the LUGPA 2024 Annual Meeting.
In part six of this roundtable series, the panelists finish their discussion by reviewing immunotherapy in prostate cancer.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
Advertisement
Advertisement
Latest News
Dr. Jayram breaks down important topics in kidney cancer from LUGPA 2024, including adjuvant pembrolizumab post-nephrectomy.
Dr. Jayram provides insights into the BCG-unresponsive and BCG-naive bladder cancer space at the LUGPA 2024 Annual Meeting.
Dr. Hafron breaks down the most important updates in upper tract urothelial carcinoma from the LUGPA 2024 Annual Meeting.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.